Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif® New Formulation (REFLEXION)

Trial Profile

Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif® New Formulation (REFLEXION)

Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLEXION
  • Sponsors Merck KGaA; Merck Serono
  • Most Recent Events

    • 28 Apr 2017 Results of post-hoc analysis conducted in the intent-to-treat population of this and REFLEX trial presented at the 69th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2017 Data from this trial will be presented at the American Academy of Neurology (AAN) 69th Annual Meeting, as reported in an EMD Serono media release.
    • 21 Apr 2016 Results of post-hoc analysis of REFLEX and REFLEXION studies assessing the effect of early versus delayed Interferon-beta-1a treatment presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top